Your browser doesn't support javascript.
loading
MicroRNA-24-3p alleviates cardiac fibrosis by suppressing cardiac fibroblasts mitophagy via downregulating PHB2.
Zhang, Yue; Wang, Zhiying; Lan, Dingming; Zhao, Jingjing; Wang, Lexun; Shao, Xiaoqi; Wang, Dongwei; Wu, Kaili; Sun, Mengxian; Huang, Xueying; Yan, Meiling; Liang, Haihai; Rong, Xianglu; Diao, Hongtao; Guo, Jiao.
Affiliation
  • Zhang Y; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Wang Z; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Lan D; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Zhao J; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Wang L; Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangzhou 510006, PR China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, PR China; Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, PR Chi
  • Shao X; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Wang D; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Wu K; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Sun M; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Huang X; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Yan M; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • Liang H; Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, PR China; Research Unit of Noninfectious Chronic Diseases in Fri
  • Rong X; Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangzhou 510006, PR China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, PR China; Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, PR Chi
  • Diao H; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address: diaohongtao94@163.com.
  • Guo J; Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangzhou 510006, PR China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, PR China; Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, PR Chi
Pharmacol Res ; 177: 106124, 2022 03.
Article in En | MEDLINE | ID: mdl-35149188
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: MicroRNAs / Prohibitins Limits: Animals Language: En Journal: Pharmacol Res Journal subject: FARMACOLOGIA Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: MicroRNAs / Prohibitins Limits: Animals Language: En Journal: Pharmacol Res Journal subject: FARMACOLOGIA Year: 2022 Document type: Article